---
authors:
- ReactomeTeam
description: Phase II of biotransformation is concerned with <b><i>conjugation</i></b>,
  that is using groups from cofactors to react with functional groups present or introduced
  from phase I on the compound. The enzymes involved are a set of transferases which
  perform the transfer of the cofactor group to the substrate. The resultant conjugation
  results in greatly increasing the excretory potential of compounds. Although most
  conjugations result in pharmacological inactivation or detoxification, some can
  result in bioactivation. Most of the phase II enzymes are located in the cytosol
  except  UDP-glucuronosyltransferases (UGT), which are microsomal. Phase II reactions
  are typically much faster than phase I reactions therefore the rate-limiting step
  for biotransformation of a compound is usually the phase I reaction.<br>Phase II
  metabolism can deal with all the products of phase I metabolism, be they reactive
  (Type I substrate) or unreactive/poorly active (Type II substrate) compounds. With
  the exception of glutathione, the conjugating species needs to be made chemically
  reactive after synthesis. The availability of the cofactor in the synthesis may
  be a rate-limiting factor in some phase II pathways as it may prevent the formation
  of enough conjugating species to deal with the substrate or it's metabolite. As
  many substrates and/or their metabolites are chemically reactive, their continued
  presence may lead to toxicity.  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=156580
  Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP4111
- /instance/WP4111
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP4111.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: Phase II of biotransformation is concerned with <b><i>conjugation</i></b>,
    that is using groups from cofactors to react with functional groups present or
    introduced from phase I on the compound. The enzymes involved are a set of transferases
    which perform the transfer of the cofactor group to the substrate. The resultant
    conjugation results in greatly increasing the excretory potential of compounds.
    Although most conjugations result in pharmacological inactivation or detoxification,
    some can result in bioactivation. Most of the phase II enzymes are located in
    the cytosol except  UDP-glucuronosyltransferases (UGT), which are microsomal.
    Phase II reactions are typically much faster than phase I reactions therefore
    the rate-limiting step for biotransformation of a compound is usually the phase
    I reaction.<br>Phase II metabolism can deal with all the products of phase I metabolism,
    be they reactive (Type I substrate) or unreactive/poorly active (Type II substrate)
    compounds. With the exception of glutathione, the conjugating species needs to
    be made chemically reactive after synthesis. The availability of the cofactor
    in the synthesis may be a rate-limiting factor in some phase II pathways as it
    may prevent the formation of enough conjugating species to deal with the substrate
    or it's metabolite. As many substrates and/or their metabolites are chemically
    reactive, their continued presence may lead to toxicity.  View original pathway
    at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=156580 Reactome].
  keywords:
  - NHABP
  - N-hydroxy-2-acetylaminofluorene
  - DHEA
  - phenylacetyl-CoA
  - 27HCHOL
  - glutamine-N-acyltransferase
  - SULT1E1 dimer
  - 'Phenyl glucuronate '
  - 'MTR '
  - 'SULT2A1 '
  - HCl
  - lithocholate sulfate
  - BIL
  - 'AHCY '
  - E2
  - N-glucuronide
  - N-centre functional
  - AcC-NAT2
  - SULTs active on DHEA
  - L-Glu
  - SULT dimers (T2)
  - PNP
  - 'MeCbl '
  - PNPB
  - TPST1,2
  - BMG
  - GSH
  - 'SULT2B1-1 '
  - methylarsonite
  - NAT2 substrate
  - L-Gln
  - 'GSTT1 '
  - 'UGT2A3 '
  - OSulf-Y97,118-PODXL2
  - S-FGSH
  - 'GGT1(381-569) '
  - phenylacetate
  - CH2O
  - 'GLYATL2 '
  - 'Benzo(a)pyrene-7,8-diol 9,10-epoxide '
  - PY
  - 'UGT2B10 '
  - 'TPST2 '
  - SLC35D1 hexamer
  - 'UGT1A1 '
  - 6xUGDH
  - 'AFXBO '
  - 'SULT1C4 '
  - NAT1 acetylated
  - BaPtDHD
  - E1
  - AS3MT
  - thioester
  - 'Nicotine N-glucuronide '
  - PPi
  - N6AMT1:TRMT112
  - adenosine
  - NH2AAF
  - SULTs active on
  - PREG
  - 'Aflatoxin exo-8,9-oxide glutathione conjugate '
  - PARA
  - MAT1A multimers
  - GSTK1 dimer
  - 4-sulfate
  - COMT
  - group substrate
  - UDP
  - IMPAD1:Mg2+
  - O-centre functional
  - GSS:Mg2+ dimer
  - UGT1A1
  - 'MAT2B '
  - sulfate
  - UDP-Glc
  - 'ACAP-GSH '
  - SAL
  - 'GSTZ1 '
  - 'GSTO1 '
  - 'UGT2B15 '
  - 'UGT2A2 '
  - BPNT1
  - 6MMP
  - forming)
  - 'NAcISNZ '
  - 'GGT7(473-662) '
  - dimethylarsinate
  - Electrophilic
  - 'UGDH '
  - 'GCLC '
  - OPRO
  - 'GSTA3 '
  - 'SULT1E1 '
  - 'NHABP '
  - GCTN
  - AKR1A1
  - DNPSG
  - glutamine
  - MAT2B:MAT2A:K+:2Mg2+
  - UDP-GlcA
  - p-nitrophenol
  - CDNB
  - 'MAT1A '
  - CysGly
  - phenylacetyl
  - 'GCLM '
  - 'ACSM4 '
  - NADPH
  - CoA-SH
  - 'NAcPAS '
  - 'GSTM1 '
  - 'GGT5(388-586) '
  - MMAIII
  - AcC-NAT1
  - G1P
  - 'GSTA1 '
  - L-Cys
  - 'GSTO2 '
  - 'IMPAD1 '
  - 'EtO '
  - 'GLYAT '
  - 'UGT3A2 '
  - O2
  - 'N-hydroxy-4-aminobiphenyl O-acetylated conjugate '
  - 'K+ '
  - 'TPST1 '
  - 3,3'-diiodothyronine
  - 'UGT1A4 '
  - TPMT
  - DAOS
  - 'UGT2B4 '
  - MMETOH
  - E1S
  - BUT
  - 'DNPSG '
  - 'ESD '
  - 'DSQ '
  - 'GSTT2B '
  - E2-SO4
  - Ade-Rib
  - T3
  - gGluCys
  - HCYS
  - GCL
  - APS
  - 'SULT6B1 '
  - PAPS
  - SULT1E1,2A1
  - 'GSTT2 '
  - 'SLC26A2 '
  - 'GLYATL1 '
  - Phenyl sulfate
  - 'PAPSS2 '
  - MPA
  - 'SULT1A2 '
  - 'TAMNG '
  - 'GLYATL3 '
  - Ac-CoA
  - SULT1A1 dimer
  - 'CHAC1 '
  - 'GGT1(1-380) '
  - SUA
  - ABHD10
  - 'S-2-(hydroxyethyl)-glutathione '
  - AAF-N-S
  - NHABP-SO4
  - MTRR:MTR(cob(I)alamin)
  - 'GGT3P(1-380) '
  - 'SLC35B2 '
  - PAP
  - conjugate
  - BME
  - 'GSTM5 '
  - PARA-SO4
  - GSSG
  - DA
  - 'HPGDS '
  - 'GSTK1 '
  - SLC35B2,3
  - 'Zn2+ '
  - 'ACAP-OGLU '
  - 'OPLAH '
  - BEZ-CoA
  - CNDP2:2Mn2+ dimer
  - CHOL
  - 8xUGP2
  - 'GSTA2 '
  - 'GSS '
  - MTRR:MTR(MeCbl)
  - MGST trimers
  - 'ACSM2B '
  - GlcA
  - NAT2
  - 'GGT7(1-472) '
  - 3,5,3'-triiodothyronine 4-sulfate
  - 'SULT4A1 '
  - 'CNDP2 '
  - SULT1A3,4 dimers
  - 'GGT6(1-?) '
  - substrate
  - ATP
  - ADP
  - NAT1
  - 6MP
  - 'ABENZ '
  - NAT1 substrate
  - GST dimers
  - PODXL2
  - NAD+
  - pregnenolone
  - cholesterol sulfate
  - 'SLC26A1 '
  - SULT1A1,A2,C2,4A1
  - CYP1A2
  - 'Benzo(a)pyrene-7,8-diol-glutathione conjugate '
  - 'MAT2A '
  - 'SLC35D1 '
  - 'UGT1A9 '
  - NAT2 acetylated
  - 'NAD+ '
  - UGT1A10
  - 'ACSM1 '
  - 'PhOH '
  - BDG
  - methylarsonate
  - UDP-GlcNAc
  - PREGS
  - 3,4DHBNZ
  - 'UGT3A1 '
  - 'GGT3P(381-568) '
  - 'TAM '
  - 'MGST3 '
  - 'SULT1C2 '
  - L-Met
  - 'Paraxanthine '
  - 'UGT1A7 '
  - SLC26A1,2
  - MP+
  - 'N4-acetylsulfanilamide '
  - 'Mg2+ '
  - 'cob(I)alamin '
  - SULT2A1 dimer
  - 'GSTM3 '
  - 'NAcPAB '
  - 'SAMD '
  - ACSM2B-like proteins
  - 'GSTM4 '
  - 'Mn2+ '
  - 'NABQI '
  - 'UGT2B11 '
  - AHCY:NAD+ tetramer
  - 'UGT1A6 '
  - GSTO1 dimer
  - LCA
  - 'GGCT '
  - 'AFMU '
  - ESD dimer
  - NNMT
  - GGT dimers
  - SULT2B1-1 dimer
  - NADH
  - PhOH
  - GCTN4OG
  - xenobiotic/medium-chain fatty acid:CoA ligases
  - 'CDNB '
  - TMT
  - GLYAT-like proteins
  - 'SULT1A3 '
  - 'GGT6(?-493) '
  - H2O
  - BaP-7,8-dione
  - ABHD14B
  - AdoHcy
  - Pi
  - 'MGST1 '
  - 'GSTM2 '
  - AMPAG
  - OPLAH
  - 'UGT2B7 '
  - Salicylate-CoA
  - 'UGT1A3 '
  - 'UGT2B17 '
  - 'PAPSS1 '
  - UGT1A1 tetramer
  - 'UGT1A8 '
  - 'SULT2B1-2 '
  - DHEA-SO4
  - 'MTRR '
  - O-glucuronide
  - GGCT dimer
  - substrate:SG
  - UGT1A3,A4,A9
  - electrophilic
  - 'SULT1B1 '
  - 'ASAL '
  - 'ACSM2A '
  - HIPA
  - 'GGT5(1-387) '
  - 'ACSM5 '
  - 'N-hydroxy-4-aminobiphenyl O-glucuronide '
  - 'UGT2B28 '
  - H+
  - 5'-monophosphate
  - arsenite(3-)
  - 'FMN '
  - 27HCHOL3S
  - PAPSS1,2
  - 'TRMT112 '
  - Gly
  - 'DSQ-OG '
  - 'GSTA4 '
  - Li+
  - 'GSTP1 '
  - UGTs (O-GlcA
  - 'N6AMT1 '
  - NADP+
  - taurolithocholate
  - SULT dimers (T3)
  - 'UGT1A5 '
  - AdoMet
  - CHAC1,2
  - AMP
  - BENZA
  - 'ISNZ '
  - 'Nicotine '
  - 'GSTA5 '
  - 'CHAC2 '
  - 'SLC35B3 '
  - DMAA
  - SO4(2-)
  - formate
  - 3H,4MBNZ
  - 'Acetaminophen (TN TYLENOL) '
  - 'FAD '
  - UTP
  - 'UGT2A1 '
  - 'SULT1A4 '
  - 'MGST2 '
  - 'SULT1A1 '
  - 'UGP2 '
  - UGT1A4
  license: CC0
  name: Phase II - Conjugation of compounds
seo: CreativeWork
title: Phase II - Conjugation of compounds
wpid: WP4111
---